B
Benjamin A. Krantz
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 8
Citations - 673
Benjamin A. Krantz is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer research & Medicine. The author has an hindex of 4, co-authored 6 publications receiving 244 citations. Previous affiliations of Benjamin A. Krantz include New York University.
Papers
More filters
Journal ArticleDOI
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Ayuko Hoshino,Ayuko Hoshino,Han Sang Kim,Han Sang Kim,Linda Bojmar,Linda Bojmar,Linda Bojmar,Kofi Ennu Gyan,Michele Cioffi,Jonathan M. Hernandez,Jonathan M. Hernandez,Jonathan M. Hernandez,Constantinos P. Zambirinis,Constantinos P. Zambirinis,Gonçalo Rodrigues,Gonçalo Rodrigues,Henrik Molina,Søren Heissel,Milica Tesic Mark,Loïc Steiner,Loïc Steiner,Alberto Benito-Martin,Serena Lucotti,Angela Di Giannatale,Katharine Offer,Miho Nakajima,Caitlin Williams,Laura Nogués,Laura Nogués,Fanny A. Pelissier Vatter,Ayako Hashimoto,Ayako Hashimoto,Ayako Hashimoto,Alexander E. Davies,Daniela Freitas,Daniela Freitas,Candia M. Kenific,Yonathan Ararso,Weston Buehring,Pernille Lauritzen,Yusuke Ogitani,Kei Sugiura,Kei Sugiura,Naoko Takahashi,Maša Alečković,Kayleen A. Bailey,Joshua S. Jolissant,Joshua S. Jolissant,Huajuan Wang,Ashton Harris,L. Miles Schaeffer,Guillermo García-Santos,Guillermo García-Santos,Zoe Posner,Vinod P. Balachandran,Yasmin Khakoo,G. Praveen Raju,Avigdor Scherz,Irit Sagi,Ruth Scherz-Shouval,Yosef Yarden,Moshe Oren,Mahathi Malladi,Mary Petriccione,Kevin C. De Braganca,Maria Donzelli,Cheryl Fischer,Stephanie Vitolano,Geraldine P. Wright,Lee Ganshaw,Mariel Marrano,Amina Ahmed,Joe DeStefano,Enrico Danzer,Michael H.A. Roehrl,Norman J. Lacayo,Theresa C. Vincent,Theresa C. Vincent,Martin R. Weiser,Mary S. Brady,Paul A. Meyers,Leonard H. Wexler,Srikanth R. Ambati,Alexander J. Chou,Emily K. Slotkin,Shakeel Modak,Stephen S. Roberts,Ellen M. Basu,Daniel Diolaiti,Benjamin A. Krantz,Benjamin A. Krantz,Fatima Cardoso,Amber L. Simpson,Michael F. Berger,Charles M. Rudin,Diane M. Simeone,Maneesh Jain,Cyrus M. Ghajar,Surinder K. Batra,Ben Z. Stanger,Jack D. Bui,Kristy A. Brown,Vinagolu K. Rajasekhar,John H. Healey,Maria de Sousa,Maria de Sousa,Kim Kramer,Sujit Sheth,Jeanine Baisch,Virginia Pascual,Todd E. Heaton,Michael P. La Quaglia,David J. Pisapia,Robert E. Schwartz,Haiying Zhang,Yuan Liu,Arti Shukla,Laurence Blavier,Yves A. DeClerck,Mark A. LaBarge,Mina J. Bissell,Thomas C. Caffrey,Paul M. Grandgenett,Michael A. Hollingsworth,Jacqueline Bromberg,Jacqueline Bromberg,Bruno Costa-Silva,Héctor Peinado,Yibin Kang,Benjamin A. Garcia,Eileen M. O'Reilly,David P. Kelsen,Tanya M. Trippett,David R. Jones,Irina Matei,William R. Jarnagin,David Lyden +136 more
TL;DR: EVP proteins can serve as reliable biomarkers for cancer detection and determining cancer type, and a panel of tumor-type-specific EVP proteins in TEs and plasma are defined, which can classify tumors of unknown primary origin.
Journal ArticleDOI
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
A. Rose Brannon,Gowtham Jayakumaran,Monica Diosdado,Juber Patel,Anna Razumova,Yu Hu,Fanli Meng,Mohammad Haque,Justyna Sadowska,Brian J. Murphy,Tessara Baldi,Ian Johnson,Ryan Ptashkin,Maysun Hasan,Preethi Srinivasan,Anoop Balakrishnan Rema,Ivelise Rijo,Aaron Agarunov,Helen Won,Dilmi Perera,David N Brown,Aliaksandra Samoila,Xiaohong Jing,Erika Gedvilaite,Julie L. Yang,Dennis Stephens,Jenna-Marie Dix,Nicole DeGroat,Khedoudja Nafa,Aijazuddin Syed,Alan Li,Emily S. Lebow,Anita S. Bowman,Donna C. Ferguson,Ying Liu,Douglas A. Mata,Rohit Sharma,Soo-Ryum Yang,Tejus Bale,Jamal Benhamida,Jason C. Chang,Snjezana Dogan,Meera Hameed,Jaclyn F. Hechtman,Christine Moung,Dara S. Ross,Efsevia Vakiani,Chad M. Vanderbilt,Jinjuan Yao,Pedram Razavi,Lillian M. Smyth,Sarat Chandarlapaty,Gopa Iyer,Wassim Abida,James J. Harding,Benjamin A. Krantz,Eileen M. O'Reilly,Helena A. Yu,Bob T. Li,Charles M. Rudin,Luis A. Diaz,David B. Solit,Maria E. Arcila,Marc Ladanyi,Brian Loomis,Dana W.Y. Tsui,Michael F. Berger,Ahmet Zehir,Ryma Benayed +68 more
TL;DR: MSK-ACCESS as mentioned in this paper is an NGS assay for detection of very low frequency somatic alterations in 129 genes and achieved 92% sensitivity in de-novo mutation calling down to 0.5% allele frequency and 99% for a priori mutation profiling.
Journal ArticleDOI
Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
TL;DR: Current and emerging blood-based biomarkers that provide a measure of disease activity and allow for minimally invasive tumor analyses are emerging, including circulating tumor DNA, exosomes, and circulating tumor cells.
Journal ArticleDOI
Pancreas adenocarcinoma: novel therapeutics
TL;DR: Various novel therapeutics under clinical development are examined with a focus on stromal disrupting agents, immunotherapeutics and DNA damage repair strategies for PDAC.
Posted ContentDOI
Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay
Angela Rose Brannon,Gowtham Jayakumaran,Monica Diosdado,Juber Patel,Anna Razumova,Yu Hu,Fanli Meng,Mohammad Haque,Justyna Sadowska,Brian J. Murphy,Tessara Baldi,Ian Johnson,Ryan Ptashkin,Maysun Hasan,Preethi Srinivasan,Anoop Balakrishnan Rema,Ivelise Rijo,Aaron Agarunov,Helen Won,Dilmi Perera,David N Brown,Aliaksandra Samoila,Xiaohong Jing,Erika Gedvilaite,Julie L. Yang,Dennis Stephens,Jenna-Marie Dix,Nicole DeGroat,Khedoudja Nafa,Aijazuddin Syed,Alan Li,Emily S. Lebow,Anita S. Bowman,Donna C. Ferguson,Ying Liu,Douglas A. Mata,Rohit Sharma,Soo-Ryum Yang,Tejus Bale,Jamal Benhamida,Jason C. Chang,Snjezana Dogan,Meera Hameed,Jaclyn F. Hechtman,Christine Moung,Dara S. Ross,Efsevia Vakiani,Chad M. Vanderbilt,JinJuan Yao,Pedram Razavi,Lillian M. Smyth,Sarat Chandarlapaty,Gopa Iyer,Wassim Abida,James J. Harding,Benjamin A. Krantz,Eileen M. O'Reilly,Helena A. Yu,Bob T. Li,Charles M. Rudin,Luis A. Diaz,David B. Solit,Maria E. Arcila,Marc Ladanyi,Brian Houck-Loomis,Dana Tsui,Michael F. Berger,Ahmet Zehir,Ryma Benayed +68 more
TL;DR: The experience illustrates the importance of analyzing a matched normal sample when interpreting cfDNA results and highlights the potential of cfDNA profiling to guide treatment selection, monitor treatment response, and identify mechanisms of treatment resistance.